Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance.
Overview
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
- The First Clinical School of Anhui University of Traditional Chinese Medicine, Hefei, China
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
Abstract
Background: Brain metastasis (BM) remains a severe and fatal complication in patients with lung cancer (LC), presenting a major therapeutic challenge. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have emerged as a cornerstone of targeted therapy, their clinical efficacy is often limited by the inevitable development of drug resistance.
Methods: We initially constructed a general atlas of the tumor microenvironment (TME) in LCBM lesions by integrating single-cell RNA sequencing (scRNA-seq) data. The sensitivity of each cell cluster to EGFR-TKIs was assessed by the “Beyondcell” method. By performing high-dimensional Weighted Gene Co-expression Network Analysis (hdWGCNA), we identified hub genes within an EGFR-TKI resistance-associated cell cluster. Finally, the functional role of the most promising candidate, ACTN1, was further investigated in a constructed osimertinib-resistant LC cell line.
Results: We identified a malignant and therapy-resistant ACTN1+ epithelial cell subcluster. Both signaling and functional enrichment analyses demonstrated marked activation of PI3K-Akt and IL-17 signaling pathways in ACTN1-high patient subgroups. Finally, we applied machine learning methods to the ACTN1-related genes to select prognostic factors. In vitro experiments confirmed the pro-resistance and pro-metastatic functions of ACTN1 in osimertinib-resistant LC cells.
Conclusion: ACTN1 was discovered to induce malignant progression and formation of EGFR-TKI resistance. Targeting ACTN1-related pathways may provide novel insights to treat LCBM and overcome intracranial EGFR-TKI resistance.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE267960, at NCBI GEO; found in the text, “Data acquisition and preprocessing”
Other data links
- ebi.ac.uk/
biostudies/ , EMBL-EBI; found in the text, “Data acquisition and preprocessing”arrayexpress - ncbi.nlm.nih.gov/
geo , NCBI; found in the text, “Data acquisition and preprocessing”
Data availability statement
The original contributions presented in the study are included in the article/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 7 authors, 5 keywords, 112 references.
Cite
This paper
Wu, W., Yang, M., Qin, J., Gui, S., Zhang, Z., Zhang, Y., & Du, Y. (2026). Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance. Frontiers in cell and developmental biology, 14, 1738641. https://
BibTeX
@article{wu2026integrati
author = {Wu, Wentian and Yang, Min and Qin, Jiaxuan and Gui, Shangjia and Zhang, Ziyu and Zhang, Yiruo and Du, Yingying},
title = {{Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance}},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = apr,
volume = {14},
pages = {1738641},
publisher = {Frontiers Media SA},
issn = {2296-634X},
doi = {10.3389/
url = {https://
pmid = {42058147},
pmcid = {PMC13122775}
}
RIS
TY - JOUR
AU - Wu, Wentian
AU - Yang, Min
AU - Qin, Jiaxuan
AU - Gui, Shangjia
AU - Zhang, Ziyu
AU - Zhang, Yiruo
AU - Du, Yingying
TI - Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance
T2 - Frontiers in cell and developmental biology
J2 - Front Cell Dev Biol
PY - 2026
DA - 2026/
VL - 14
SP - 1738641
SN - 2296-634X
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance",
"container-title": "Frontiers in cell and developmental biology",
"author": [
{
"family": "Wu",
"given": "Wentian"
},
{
"family": "Yang",
"given": "Min"
},
{
"family": "Qin",
"given": "Jiaxuan"
},
{
"family": "Gui",
"given": "Shangjia"
},
{
"family": "Zhang",
"given": "Ziyu"
},
{
"family": "Zhang",
"given": "Yiruo"
},
{
"family": "Du",
"given": "Yingying"
}
],
"container-title-short":
"volume": "14",
"page": "1738641",
"DOI": "10.3389/
"PMID": "42058147",
"PMCID": "PMC13122775",
"ISSN": "2296-634X",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
14
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1186/s12935-026-04370-8
- Machine learning-based prognostic model and single-cell transcriptomic integration for identifying brain metastasis-associated malignant subpopulations and potential therapeutic targets in lung adenocarcinoma.Journal: Cancer cell internationalIn common: genetics / omics, other condition, 14 references
- [2] doi:10.1186/s43556-025-00251-0
- Cancer brain metastasis: molecular mechanisms and therapeutic strategies.Journal: Molecular biomedicineIn common: other condition, 12 references
- [3] doi:10.1038/s41419-026-08807-w [code]
- Single-cell profiling reveals distinct populations of tumor-associated macrophages and metastatic tumor cells in breast cancer brain metastasis.Journal: Cell death & diseaseIn common: genetics / omics, other condition, cellular / molecular, 6 references
- [4] doi:10.21037/jtd-2025-1224
- Single-cell and spatial transcriptome landscapes reveal the spatial immune defense pattern shared by primary and brain metastatic lung adenocarcinoma.Journal: Journal of thoracic diseaseIn common: genetics / omics, other condition, 5 references
- [5] doi:10.1111/cpr.13697 [code]
- Single-cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target.Journal: Cell proliferationIn common: genetics / omics, other condition, cellular / molecular, 6 references
- [6] doi:10.1038/s41467-026-68748-y
- A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.Journal: Nature communicationsIn common: other condition, cellular / molecular, 6 references
- [7] doi:10.7150/ijbs.127108
- Oligodendrocyte-secreted
ERBB3 Mediates the Competitive Uptake of Copper Ions by Tumor Cells to Promote Brain Metastasis in Lung Cancer. Journal: International journal of biological sciencesIn common: other condition, cellular / molecular, 5 references - [8] doi:10.3390/cancers17040581
- Construction of a miRNA Panel for Differentiating Lung Adenocarcinoma Brain Metastases and Glioblastoma.Journal: CancersIn common: genetics / omics, other condition, 4 references
- [9] doi:10.1038/s41467-026-70715-6
- Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibitor responses.Journal: Nature communicationsIn common: other condition, cellular / molecular, 5 references
- [10] doi:10.1158/2159-8290.cd-21-0910
- Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.Journal: Cancer discoveryIn common: other condition, cellular / molecular, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
